One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
Price : 100$- Special Price : 50$
Trends in nephrology: cardiovascular kidney-metabolic syndrome
doi : 10.1093/ndt/gfaf250
Volume 41, Issue 6, June 2026
Disconnected universes: advanced kidney research versus absence of basic kidney care in high income countries
doi : 10.1093/ndt/gfag039
Albuminuria or proteinuria in glomerular disease and CKD—which one to use?
doi : 10.1093/ndt/gfag020
Nephrotoxicity of conventional chemotherapeutics: part 1—platinum compounds and antimetabolite agents
doi : 10.1093/ndt/gfaf251
Biology of drug-induced acute nephrotoxicity: focus on the tubulointerstitium
doi : 10.1093/ndt/gfaf266
Telitacicept targets Gd-IgA1 and autoantibody-producing B cells in IgA nephropathy
doi : 10.1093/ndt/gfag001
Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease
doi : 10.1093/ndt/gfaf230
The non-steroidal mineralocorticoid receptor blocker esaxerenone reduces glomerular hyperfiltration and albuminuria
doi : 10.1093/ndt/gfaf232
Kidney replacement therapy for men and women according to the ERA Registry and the USRDS
doi : 10.1093/ndt/gfaf233
Kidney replacement therapy trajectories of patients with kidney failure: an ERA Registry study
doi : 10.1093/ndt/gfaf236
Body roundness index and mortality risk in patients with chronic kidney disease: moving beyond the obesity paradox
doi : 10.1093/ndt/gfaf237
Troxerutin is a novel osmotic agent for peritoneal dialysis with protective cardiovascular actions
doi : 10.1093/ndt/gfaf249
Randomized controlled trials in Europe: a call to action to protect national healthcare systems from the upcoming tsunami of kidney failure
doi : 10.1093/ndt/gfag007
Meta-analyses overgeneralize SGLT2 inhibitor effectiveness in population with low albuminuria, no diabetes, no heart failure and no atherovascular heart disease
doi : 10.1093/ndt/gfag009
Updated data of rituximab-associated agranulocytosis and safety of rituximab re-administration in paediatric nephrotic syndrome
doi : 10.1093/ndt/gfag048
